Clinical Trial Update: Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the combination of carfilzomib and vorinostat in relapsed or refractory lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• Carfilzomib (carfilzomib)
• Vorinostat (vorinostat)

Snippet

Sponsor: University of Rochester | Conditions: Lymphoma | Phase 1 | Status: COMPLETED